Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients With Locally Advanced Cutaneous Squamous Cell Carcinoma. J of Skin 2018, 2, S77. https://doi.org/10.25251/skin.2.supp.77.